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Game Changers
AN UPDATE IN AORTIC VALVE INTERVENTION 
AND EARLY DISCHARGE
Dr H Douglas, Dr M Spence
Department of Cardiology, Royal Victoria Hospital, Belfast, 
BT12 6BA
Severe aortic stenosis is common and carries significant 
morbidity and mortality in an ever-growing elderly 
population. 
It is now fifteen years since the advent of Transcatheter Aortic 
Valve Implantation (TAVI). The first ever case was performed 
in 2002.1   Since then data from randomised controlled trials 
supporting favourable outcomes with TAVI for patients 
in whom surgical aortic valve replacement is considered 
high risk have led to its inclusion in the latest International 
guidelines for management of valvular heart disease2.  
The TAVI programme at the Royal Victoria Hospital was 
commenced in 2008. Over 700 cases have been performed 
to date. All cases are considered at our regional heart team 
meeting (comprising a minimum of general cardiologist, 
interventional cardiologist and cardiac surgeons) and 
implementation of our early discharge pathway in 2013 has 
already shown locally that in a cohort of carefully selected 
patients next day and even same day discharge can be safely 
facilitated3. Currently, cases from Belfast are included in 
ongoing international registry work around the feasibility and 
safety of early discharge4.   
The TAVI programme continues to thrive, providing patients 
evaluated by our heart team with a transcatheter solution with 
short recovery time, reduced length of stay in hospital and 
good outcomes.
1.  Cribier A et al.  Percutaneous transcatheter implantation of an 
aortic valve prosthesis for calcific aortic stenosis: first human case 
description. Circulation. 2002; 106: 3006–3008
2.  Nishimura RA et al. “2014 AHA/ACC Guideline for the management of 
patients with valvular heart disease.”, J Am Coll Cardiol. 2014; 63(22): 
e57-e185.
3.  Noad RL et al. Pathway to earlier discharge following TAVI: Assessment 
of safety and resource utilization. Catheter Cardiovasc Interv. 2016; 
87(1):134-42. 
4.  https://clinicaltrials.gov/ct2/show/NCT02404467 (Downloaded 
05/07/2017).
SENTINEL BIOPSY IN VULVAL CANCER – 
ESTABLISHING A REGIONAL SERVICE IN 
NORTHERN IRELAND 
Dr F McCloskey,Dr T Lynch, Dr H Nagar, Dr E Murtagh
Departments of Radiology, Nuclear Medicine and 
Gynaecology, Belfast City Hospital, BT9 7AB
Sentinel node biopsy has an established role in the 
management of breast cancer and an evolving role in 
melanoma management.   It now also plays a key part in the 
management of selected vulval cancers.1+2 
It was introduced to Northern Ireland in 2015 and to date 
20 patients with vulval cancer, ranging from FIGO stage 
1b-3c, have received sentinel node localisation, using a peri-
tumoural injection of Tecnetium-99 radiolabelled nanocolloid. 
The sentinel nodes were identified using a GE SPECT CT 
gamma camera system. In theatre, nodes are located using 
a hand-held detector, localising the most proximal draining 
node (sentinel) from the tumour. 90% of sentinel node 
biopsies were negative for disease. The 2 biopsy-positive 
patients were of a higher FIGO stage, they underwent groin 
node dissection and remain disease free. 
The GROINSS-V study found that 1-5 % of vulval cancers 
will metastasise to non-sentinel lymph nodes.  This was 
reflected in our regional experience, with one biopsy-negative 
patient presenting with metastatic disease within 1 year.3  This 
should be interpreted in the context of a 10-15% recurrence 
rate in vulval cancer overall.
Careful patient selection in accordance with local guidelines 
and patient counselling preoperatively is of utmost 
importance.  Implementation of this technique has led to a 
dramatic reduction in rates of groin node dissection with its 
associated morbidity.
1.   Covens et al.  Sentinel node biopsy in vulvar cancer:  Systemic review, 
meta-analysis and guideline recommendations.   Gyneacologic Oncology, 
2015; 137(2): 351-61
2.   Guidelines for the diagnosis and management of vulval carcinoma, 
RCOG guidelines, May 2014. 
3.  Oonk MH et al.  Size of sentinel-node metastasis and chances of non-
sentinel-node involvement and survival in early stage vulvar cancer: 
results from GROINSS-V, a multicentre observational study.  Lancet 
2010; 11(7): 646-52.
IMMUNOTHERAPY FOR LUNG CANCER – A 
GAMECHANGER!
Dr GM Walls, Dr GG Hanna 
Department of Oncology, North West Cancer Centre, 
Altnagelvin and Belfast City Hospital
Cancer evades the ability of the immune system by turning on 
cell surface proteins which turn off immune-surveillance cells 
such as T-helper cells1. Immunotherapy treatments such as the 
immune checkpoint inhibitors overcome cancer’s ability to 
switch off the immune response to altered cells. Randomised 
trials studying immunotherapy have demonstrated a patient 
benefit across a number of disease sites, in both curative and 
non-curative settings.
Pembrolizumab, a monoclonal antibody for the PD-1 receptor 
(B cells and T cells), has been NICE-approved in 2017 
for the treatment of metastatic non-small-cell lung cancer 
(NSCLC) in second-line therapy and is available via the 
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cancer drugs fund in England for first line therapy. Immune 
checkpoints such as the PD-1 receptor down-modulate the 
immune response as described above. The KEYNOTE-010 
trial showed that pembrolizumab was better than standard 
second-line chemotherapy in terms of disease progression 
and toxicity2. The particularly impressive outcome from 
many such immunotherapy studies is controlled or absent 
disease 5 years after starting treatment in a substantial cohort 
of patients. 
Adverse effects from immune checkpoint inhibitors are 
largely related to overstimulation of the immune system and 
include pneumonitis, hepatitis, endocrinopathy, skin rashes 
and gastrointestinal toxicity3. There is growing evidence 
that radiotherapy delivered before or with immunotherapy, 
increases the likelihood a clinical response, and further 
investigations are under way1.
1. Hanna GG, Coyle VM, Prise KM. Immune modulation in 
advanced radiotherapies: targeting out-of-field effects. Cancer Lett 
2015;368(2):246-51.
2. Herbst RS, Bass P, Kim DW, et al. Pembrolizumab versus docetaxel 
for previously treated, PD-L1-positive, advanced non-small-cell lung 
cancer (KEYNOTE-010): a randomised controlled trial. Lancet Oncol 
2016;387:1540-50.
3. Hanna GG, Illidge T. Radiotherapy and immunotherapy combinations 
in non-small cell lung cancer: a promising future? Clin Oncol (R Coll 
Radiol) 2016;28(11):726-31. 
